Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis

Authors: Joelle M Fenger, Misty D Bear, Stefano Volinia, Tzu-Yin Lin, Bonnie K Harrington, Cheryl A London, William C Kisseberth

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

While microRNA (miRNA) expression is known to be altered in a variety of human malignancies contributing to cancer development and progression, the potential role of miRNA dysregulation in malignant mast cell disease has not been previously explored. The purpose of this study was to investigate the potential contribution of miRNA dysregulation to the biology of canine mast cell tumors (MCTs), a well-established spontaneous model of malignant mast cell disease.

Methods

We evaluated the miRNA expression profiles from biologically low-grade and biologically high-grade primary canine MCTs using real-time PCR-based TaqMan Low Density miRNA Arrays and performed real-time PCR to evaluate miR-9 expression in primary canine MCTs, malignant mast cell lines, and normal bone marrow-derived mast cells (BMMCs). Mouse mast cell lines and BMMCs were transduced with empty or pre-miR-9 expressing lentiviral constructs and cell proliferation, caspase 3/7 activity, and invasion were assessed. Transcriptional profiling of cells overexpressing miR-9 was performed using Affymetrix GeneChip Mouse Gene 2.0 ST arrays and real-time PCR was performed to validate changes in mRNA expression.

Results

Our data demonstrate that unique miRNA expression profiles correlate with the biological behavior of primary canine MCTs and that miR-9 expression is increased in biologically high grade canine MCTs and malignant cell lines compared to biologically low grade tumors and normal canine BMMCs. In transformed mouse malignant mast cell lines expressing either wild-type (C57) or activating (P815) KIT mutations and mouse BMMCs, miR-9 overexpression significantly enhanced invasion but had no effect on cell proliferation or apoptosis. Transcriptional profiling of normal mouse BMMCs and P815 cells possessing enforced miR-9 expression demonstrated dysregulation of several genes, including upregulation of CMA1, a protease involved in activation of matrix metalloproteases and extracellular matrix remodeling.

Conclusions

Our findings demonstrate that unique miRNA expression profiles correlate with the biological behavior of canine MCTs. Furthermore, dysregulation of miR-9 is associated with MCT metastasis potentially through the induction of an invasive phenotype, identifying a potentially novel pathway for therapeutic intervention.
Appendix
Available only for authorised users
Literature
1.
Horny HP, Sotlar K, Valent P: Mastocytosis: state of the art. Pathobiology. 2007, 27 (2): 121-132.CrossRef
2.
London CA, Seguin B: Mast cell tumors in the dog. Vet Clin North Am Small Anim Pract. 2003, 33 (3): 473-489. 10.1016/S0195-5616(03)00003-2.CrossRefPubMed
3.
Valent P, Akin C, Sperr WR, Mayerhofer M, Födinger M, Fritsche-Polanz R, Sotlar K, Escribano L, Arock M, Horny HP, Metcalfe DD: Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005, 46 (1): 35-48. 10.1080/10428190400010775.CrossRefPubMed
4.
Tsujimura T, Furitsu T, Morimoto M, Isozaki K, Nomura S, Matsuzawa Y, KITamura Y, Kanakura Y: Ligand-independent activation of c-KIT receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood. 1994, 83 (9): 2619-2626.PubMed
5.
Tsujimura T, Furitsu T, Morimoto M, Kanayama Y, Nomura S, Matsuzawa Y, KITamura Y, Kanakura Y: Substitution of an aspartic acid results in constitutive activation of c-KIT receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol. 1995, 106 (4): 377-385. 10.1159/000236870.CrossRefPubMed
6.
Downing S, Chien MB, Kass PH, Moore PE, London CA: Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-KIT in mast cell tumors of dogs. Am J Vet Res. 2002, 63 (12): 1718-1723. 10.2460/ajvr.2002.63.1718.CrossRefPubMed
7.
Zemke D, Yamini B, Yuzbasiyan-Gurkan V: Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol. 2002, 39 (5): 529-535. 10.1354/vp.39-5-529.CrossRefPubMed
8.
Letard S, Yang Y, Hanssens K, Palmérini F, Leventhal PS, Guéry S, Moussy A, Kinet JP, Hermine O, Dubreuil P: Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res. 2008, 6 (7): 1137-1145. 10.1158/1541-7786.MCR-08-0067.CrossRefPubMed
9.
Lin TY, London CA: A functional comparison of canine and murine bone marrow derived cultured mast cells. Vet Immunol Immunopathol. 2006, 114 (3–4): 320-334.CrossRefPubMed
10.
Leibman NF, Lana SE, Hansen RA, Powers BE, Fettman MJ, Withrow SJ, Ogilvie GK: Identification of matrix metalloproteinases in canine cutaneous mast cell tumors. J Vet Intern Med. 2000, 14 (6): 583-586. 10.1111/j.1939-1676.2000.tb02280.x.CrossRefPubMed
11.
Giantin M, Aresu L, Benali S, Aricò A, Morello EM, Martano M, Vascellari M, Castagnaro M, Lopparelli RM, Zancanella V, Granato A, Mutinelli F, Dacasto M: Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases and vascular endothelial growth factor in canine mast cell tumours. J Comp Pathol. 2012, 147 (4): 419-429. 10.1016/j.jcpa.2012.01.011.CrossRefPubMed
12.
Schlieben P, Meyer A, Weise C, Bondzio A, Einspanier R, Gruber AD, Klopfleisch R: Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours. Vet J. 2012, 194 (2): 210-214. 10.1016/j.tvjl.2012.04.002.CrossRefPubMed
13.
Garzon R, Fabbri M, Cimmino A, Calin GA, Croce C: MicroRNA expression and function in cancer. Trends Mol Med. 2006, 12 (12): 580-587. 10.1016/j.molmed.2006.10.006.CrossRefPubMed
14.
Monticelli S, Ansel KM, Xiao C, Socci ND, Krichevsky AM, Thai TH, Rajewsky N, Marks DS, Sander C, Rajewsky K, Rao A, Kosik KS: MicroRNA profiling of the murine hematopoietic system. Genome Biol. 2005, 6 (8): R71-10.1186/gb-2005-6-8-r71.CrossRefPubMedPubMedCentral
15.
Mayoral RJ, Pipkin ME, Pachkov M, van Nimwegen E, Rao A, Monticelli S: MicroRNA-221-222 regulate the cell cycle in mast cells. J Immunol. 2009, 182 (1): 433-445.CrossRefPubMedPubMedCentral
16.
Mayoral RJ, Deho L, Rusca N, Bartonicek N, Saini HK, Enright AJ, Monticelli S: MiR-221 influences effector functions and actin cytoskeleton in mast cells. PLoS One. 2011, 6 (10): e26133-10.1371/journal.pone.0026133.CrossRefPubMedPubMedCentral
17.
Lee YN, Brandal S, Noel P, Wentzel E, Mendell JT, McDevitt MA, Kapur R, Carter M, Metcalfe DD, Takemoto CM: KIT signaling regulates MITF expression through miRNAs in normal and malignant cell proliferation. Blood. 2011, 117 (13): 3629-3640. 10.1182/blood-2010-07-293548.CrossRefPubMedPubMedCentral
18.
Lin TY, Rush LJ, London CA: Generation and characterization of bone marrow-derived cultured canine mast cells. Vet Immunol Immunopathol. 2006, 113 (1–2): 37-52.CrossRefPubMed
19.
Tsai M, Miyamoto M, Tam SY, Wang ZS, Galli SJ: Detection of mouse mast cell-associated protease mRNA. Heparinase treatment greatly improves RT-PCR of tissues containing mast cell heparin. Am J Pathol. 1995, 146 (2): 335-343.PubMedPubMedCentral
20.
Guerau-de-Arellano M, Smith KM, Godlewski J, Liu Y, Winger R, Lawler SE, Whitacre CC, Racke MK, Lovett-Racke AE: Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain. 2011, 134 (Pt 12): 3578-3589.CrossRefPubMed
21.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001, 25 (4): 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
22.
Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998, 95 (25): 14863-14868. 10.1073/pnas.95.25.14863.CrossRefPubMedPubMedCentral
23.
Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA: Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer. 2009, 9: 81-10.1186/1471-2407-9-81.CrossRefPubMedPubMedCentral
24.
Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA: AR-42, a novel HDAC inhibitor, exhibits biological activity against malignant mast cell lines via down-regulation of constitutively activated KIT. Blood. 2010, 115 (21): 4217-4225. 10.1182/blood-2009-07-231985.CrossRefPubMedPubMedCentral
25.
Thulin P, Wei T, Werngren O, Cheung L, Fisher RM, Grander D, Corocran M, Ehrenborg E: MicroRNA-9 regulates the expression of peroxisome proliferator-activated receptor δ in human monocytes during the inflammatory response. Int J Mol Med. 2013, 31 (5): 1003-1010.PubMedPubMedCentral
26.
Boggs RM, Wright ZM, Stickney MJ, Porter WW, Murphy KE: MicroRNA expression in canine mammary cancer. Mamm Genome. 2008, 19 (7–8): 561-569.CrossRefPubMed
27.
Uhl E, Krimer P, Schliekelman P, Tompkins SM, Suter S: Identification of altered microRNA expression in canine lymphoid cell lines and cases of B- and T-cell lymphomas. Genes Chromosomes Cancer. 2011, 50 (11): 950-967. 10.1002/gcc.20917.CrossRefPubMed
28.
Gioia G, Mortarino M, Gelain ME, Albonico F, Ciusani E, Forno I, Marconato L, Martini V, Comazzi S: Immunophenotype-related microRNA expression in canine chronic lymphocytic leukemia. Vet Immunol Immunopathol. 2011, 142 (3–4): 228-235.CrossRefPubMed
29.
Noguchi S, Mori T, Hoshino Y, Yamada N, Maruo K, Akao Y: MicroRNAs as tumour suppressors in canine and human melanoma cells and as a prognostic factor in canine melanomas. Vet Comp Oncol. 2013, 11 (2): 113-123. 10.1002/vco.306.CrossRefPubMed
30.
Noguchi S, Mori T, Hoshino Y, Yamada N, Nakagawa T, Sasaki N, Akao Y, Maruo K: Comparative study of anti-oncogenic microRNA-145 in canine and human malignant melanoma. J Vet Med Sci. 2012, 74 (1): 1-8. 10.1292/jvms.11-0264.CrossRefPubMed
31.
Vinall RL, Kent MS, DeVere White RW: Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. Am J Vet Res. 2012, 73 (10): 1626-1633. 10.2460/ajvr.73.10.1626.CrossRefPubMed
32.
33.
Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA: MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010, 12 (3): 247-256.PubMedPubMedCentral
34.
Gravgaard KH, Lyng MB, Laenkholm AV, Søkilde R, Nielsen BS, Litman T, Ditzel HJ: The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat. 2012, 134 (1): 207-217. 10.1007/s10549-012-1969-9.CrossRefPubMed
35.
Wang J, Zhao H, Tang D, Wu J, Yao G, Zhang Q: Overexpressions of microRNA-9 and microRNA-200c in human breast cancers are associated with lymph node metastasis. Cancer Biother Radiopharm. 2013, 28 (4): 283-288. 10.1089/cbr.2012.1293.CrossRefPubMedPubMedCentral
36.
Tan HX, Wang Q, Chen LZ, Huang XH, Chen JS, Fu XH, Cao LQ, Chen XL, Li W, Zhang LJ: MicroRNA-9 reduces cell invasion and E-cadherin secretion in SK-Hep-1 cells. Med Oncol. 2010, 27 (3): 654-660. 10.1007/s12032-009-9264-2.CrossRefPubMed
37.
Sun Z, Han Q, Zhou N, Wang S, Lu S, Bai C, Zhao RC: MicroRNA-9 enhances migration and invasion through KLF17 in hepatocellular carcinoma. Mol Oncol. 2013, 7 (5): 884-894. 10.1016/j.molonc.2013.04.007.CrossRefPubMed
38.
Lu MH, Huang CC, Pan MR, Chen HH, Hung WC: Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9. Clin Cancer Res. 2012, 18 (23): 6416-6425. 10.1158/1078-0432.CCR-12-0832.CrossRefPubMed
39.
Zhu L, Chen H, Zhou D, Bai R, Zheng S, Ge W: MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. Med Oncol. 2012, 29 (2): 1037-1043. 10.1007/s12032-011-9975-z.CrossRefPubMed
40.
Laios A, O’Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D’Arcy T, McGuinness E, Sheils O, Sheppard B, O’ Leary J: Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008, 7: 35-10.1186/1476-4598-7-35.CrossRefPubMedPubMedCentral
41.
Zheng L, Qi T, Yang D, Qi M, Li D, Xiang X, Huang K, Tong Q: MicroRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1. PLoS One. 2013, 8 (1): e55719-10.1371/journal.pone.0055719.CrossRefPubMedPubMedCentral
42.
Guo LM, Pu Y, Han Z, Liu T, Li YX, Liu M, Li X, Tang H: MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J. 2009, 276 (19): 5537-5546.CrossRefPubMed
43.
Rotkrua P, Akiyama Y, Hashimoto Y, Otsubo T, Yuasa Y: MiR-9 downregulates CDX2 expression in gastric cancer cells. Int J Cancer. 2011, 129 (11): 2611-2620. 10.1002/ijc.25923.CrossRefPubMed
44.
Diamond MS, Farzan M: The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol. 2013, 13 (1): 46-57.CrossRefPubMed
45.
Guijarro MV, Leal JF, Fominaya J, Blanco-Aparicio C, Alonso S, Lleonart M, Castellvi J, Ruiz L, Ramon y Cajal S, Carnero A: MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis. 2007, 28 (8): 1646-1652. 10.1093/carcin/bgm083.CrossRefPubMed
46.
47.
Guijarro MV, Leal JF, Blanco-Aparicio C, Alonso S, Fominaya J, Lleonart M, Castellvi J, Carnero A, Ramon y Cajal S: MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis. 2007, 28 (10): 2096-2104. 10.1093/carcin/bgm124.CrossRefPubMed
48.
49.
He SH, Chen P, Chen HQ: Modulation of enzymatic activity of human mast cell tryptase and chymase by protease inhibitors. Acta Pharmacol Sin. 2003, 24 (9): 923-929.PubMed
50.
Bashkin P, Razin E, Eldor A, Vlodavsky I: Degranulating mast cells secrete an endoglycosidase that degrades heparan sulfate in subendothelial extracellular matrix. Blood. 1990, 75 (11): 2204-2212.PubMed
51.
Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I: The heparanase system and tumor metastasis: is heparanase the seed and soil?. Cancer Metastasis Rev. 2011, 30: 253-268. 10.1007/s10555-011-9288-x.CrossRefPubMed
52.
Hunter KE, Palermo C, Kester JC, Simpson K, Li J-P, Tang LH, Klimstra DS, Vlodavsky I, Joyce JA: Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors. Oncogene. 2013, 1-10. doi:10.1038/onc.2013.142
Metadata
Title
Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis
Authors
Joelle M Fenger
Misty D Bear
Stefano Volinia
Tzu-Yin Lin
Bonnie K Harrington
Cheryl A London
William C Kisseberth
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-84

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells

Review

MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers

Research article

Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow

Research article

Prophylactic cranial irradiation for patients with small-cell lung cancer: a systematic review of the literature with meta-analysis

Research article

Time trends in socioeconomic inequalities in cancer mortality: results from a 35 year prospective study in British men

Research article

Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits